- Home
- BRW vs KMDA Comparison
BRW vs KMDA Comparison
Compare BRW & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRW
- KMDA
- Stock Information
- Founded
- BRW 1987
- KMDA 1990
- Country
- BRW United States
- KMDA Israel
- Employees
- BRW N/A
- KMDA N/A
- Industry
- BRW Trusts Except Educational Religious and Charitable
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- BRW Finance
- KMDA Health Care
- Exchange
- BRW Nasdaq
- KMDA Nasdaq
- Market Cap
- BRW 333.0M
- KMDA 399.7M
- IPO Year
- BRW N/A
- KMDA N/A
- Fundamental
- Price
- BRW $8.12
- KMDA $7.88
- Analyst Decision
- BRW
- KMDA Strong Buy
- Analyst Count
- BRW 0
- KMDA 3
- Target Price
- BRW N/A
- KMDA $14.67
- AVG Volume (30 Days)
- BRW 222.1K
- KMDA 83.3K
- Earning Date
- BRW 01-01-0001
- KMDA 08-13-2025
- Dividend Yield
- BRW 15.59%
- KMDA 2.54%
- EPS Growth
- BRW N/A
- KMDA 31.21
- EPS
- BRW N/A
- KMDA 0.28
- Revenue
- BRW N/A
- KMDA $167,235,000.00
- Revenue This Year
- BRW N/A
- KMDA $14.51
- Revenue Next Year
- BRW N/A
- KMDA $9.31
- P/E Ratio
- BRW N/A
- KMDA $27.89
- Revenue Growth
- BRW N/A
- KMDA 11.83
- 52 Week Low
- BRW $7.15
- KMDA $5.08
- 52 Week High
- BRW $8.30
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- BRW 70.70
- KMDA 69.92
- Support Level
- BRW $7.85
- KMDA $7.61
- Resistance Level
- BRW $8.18
- KMDA $7.86
- Average True Range (ATR)
- BRW 0.09
- KMDA 0.20
- MACD
- BRW 0.02
- KMDA 0.04
- Stochastic Oscillator
- BRW 84.62
- KMDA 77.46
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.